CSL Limited (CSLLY) 是一家上市公司 屬於 醫療保健 板塊,經營於 生物科技 產業. 公司總部位於 Melbourne, VIC, 澳大利亚. 現任CEO為 Gordon Naylor DipCompSc.
CSLLY 擁有 IPO日期為 2009-12-29, 32,698 名全職員工, 在 Other OTC, 市值為 $95.92B.
CSL Limited is a global biopharmaceutical company headquartered in Parkville, Australia, with operations across the United States, Europe, China, and other international markets. The company operates through two primary divisions: CSL Behring, which specializes in plasma-derived and recombinant therapies for immunodeficiency, bleeding disorders, hereditary angioedema, and neurological conditions, and Seqirus, which focuses on non-plasma biotherapeutics and influenza-related products. CSL Limited researches, develops, manufactures, and distributes a comprehensive portfolio of biopharmaceutical products while also generating revenue through licensing and royalty agreements. Founded in 1916, the company has established itself as a leader in the biopharmaceutical industry through its innovative therapeutic solutions and global market presence.